Argent Trust Co reduced its stake in Amgen Inc. by 29.4% in the third quarter, selling 9,070 shares and ending with 21,826 shares valued at $6.159 million. Despite this reduction, Amgen reported strong Q4 results, beating EPS and revenue expectations, and raised its quarterly dividend. The company also maintains a “Moderate Buy” analyst consensus with an average target price of $351.76.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Argent Trust Co Lowers Stock Holdings in Amgen Inc. $AMGN
Argent Trust Co reduced its stake in Amgen Inc. by 29.4% in the third quarter, selling 9,070 shares and ending with 21,826 shares valued at $6.159 million. Despite this reduction, Amgen reported strong Q4 results, beating EPS and revenue expectations, and raised its quarterly dividend. The company also maintains a “Moderate Buy” analyst consensus with an average target price of $351.76.